Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2)

T. Kucharzik; A. Dignass; R. Atreya; B. Bokemeyer; P. Esters; K. Herrlinger; K. Kannengiesser; P. Kienle; J. Langhorst; A. Lügering; S. Schreiber; A. Stallmach; J. Stein; A. Sturm; N. Teich; B. Siegmund; Collaborators

doi:10.1055/a-2271-0994

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2024; 62(05): 769-858
DOI: 10.1055/a-2271-0994

Leitlinie

Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2)

Januar 2024 – AWMF-Registriernummer: 021-009

T. Kucharzik^*

¹Klinik für Allgemeine Innere Medizin und Gastroenterologie, Städtisches Klinikum Lüneburg, Lüneburg, Deutschland

,

A. Dignass^*

²Medizinische Klinik I, Agaplesion Markus Krankenhaus, Frankfurt, Deutschland

,

R. Atreya

³Medizinische Klinik 1 Gastroent., Pneumologie, Endokrin., Universitätsklinikum Erlangen, Erlangen, Deutschland

,

B. Bokemeyer

⁴Interdisziplinäres Crohn Colitis Centrum Minden – ICCCM, Minden, Deutschland

,

P. Esters

²Medizinische Klinik I, Agaplesion Markus Krankenhaus, Frankfurt, Deutschland

,

K. Herrlinger

⁵Innere Medizin I, Asklepios Klinik Nord, Hamburg, Deutschland

,

K. Kannengiesser

¹Klinik für Allgemeine Innere Medizin und Gastroenterologie, Städtisches Klinikum Lüneburg, Lüneburg, Deutschland

,

P. Kienle

⁶Abteilung für Allgemein- und Viszeralchirurgie, Theresienkrankenhaus, Mannheim, Deutschland

,

J. Langhorst

⁷Klinik für Integrative Medizin und Naturheilkunde, Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg, Deutschland

,

A. Lügering

⁸Medizinisches Versorgungszentrum Portal 10, Münster, Deutschland

,

S. Schreiber

⁹Klinik für Innere Medizin I, Universitätsklinikum Schleswig Holstein, Kiel, Deutschland

,

A. Stallmach

¹⁰Klinik für Innere Medizin IV Gastroenterologie, Hepatologie, Infektiologie, Universitätsklinikum Jena, Jena, Deutschland

,

J. Stein

¹¹Abteilung Innere Medizin mit Schwerpunkt Gastroenterologie, Krankenhaus Sachsenhausen, Frankfurt, Deutschland

,

A. Sturm

¹²Klinik für Innere Medizin mit Schwerpunkt Gastroenterologie, DRK Kliniken Berlin Westend, Berlin, Deutschland

,

N. Teich

¹³Internistische Gemeinschaftspraxis, Leipzig, Deutschland

,

B. Siegmund

¹⁴Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité Campus Benjamin Franklin – Universitätsmedizin Berlin, Berlin, Deutschland

,

Collaborators

› Institutsangaben

Abstract

Schlüsselwörter

chronisch-entzündliche Darmerkrankungen - CED - Diagnose - Therapie - Remission - Remissionserhaltung

Volltext

Referenzen

Literatur
1 OCEBM Levels of Evidence Working Group = Jeremy Howick ICJLL, Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard and Mary Hodgkinson. OCEBM Levels of Evidence Working Group*. “The Oxford Levels of Evidence 2”. 2011
2 Marteau P, Probert CS, Lindgren S. et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-965
3 Silverberg MS, Satsangi J, Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5-36
4 Ekbom A, Helmick C, Zack M. et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233
5 Soetikno RM, Lin OS, Heidenreich PA. et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54
6 Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?. Aliment Pharmacol Ther 2004; 20: 1035-1043
7 Takeuchi K, Smale S, Premchand P. et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202
8 Sandborn WJ, Stenson WF, Brynskov J. et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4: 203-211
9 Korzenik JR, Podolsky DK. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 157-159
10 Ho GT, Chiam P, Drummond H. et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-330
11 Faubion Jr. WA, Loftus Jr. EV, Harmsen WS. et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260
12 Toruner M, Loftus Jr. EV, Harmsen WS. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936
13 Mahid SS, Minor KS, Soto RE. et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-1471
14 Hoie O, Wolters F, Riis L. et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102: 1692-1701
15 Beaugerie L, Massot N, Carbonnel F. et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001; 96: 2113-2116
16 Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004; 10: 848-859
17 Florin TH, Pandeya N, Radford-Smith GL. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 2004; 53: 973-979
18 Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24 (Suppl. 03) 2-10
19 Merrett MN, Mortensen N, Kettlewell M. et al. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut 1996; 38: 362-364
20 Joelsson M, Benoni C, Oresland T. Does smoking influence the risk of pouchitis following ileal pouch anal anastomosis for ulcerative colitis?. Scand J Gastroenterol 2006; 41: 929-933
21 Loftus Jr. EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517
22 Rutgeerts P, D’Haens G, Hiele M. et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994; 106: 1251-1253
23 Frisch M, Johansen C, Mellemkjaer L. et al. Appendectomy and subsequent risk of inflammatory bowel diseases. Surgery 2001; 130: 36-43
24 Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA. Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis 2002; 8: 277-286
25 Cosnes J, Carbonnel F, Beaugerie L. et al. Effects of appendicectomy on the course of ulcerative colitis. Gut 2002; 51: 803-807
26 Radford-Smith GL, Edwards JE, Purdie DM. et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut 2002; 51: 808-813
27 Childers RE, Eluri S, Vazquez C. et al. Family history of inflammatory bowel disease among patients with ulcerative colitis: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 1480-1497
28 Henriksen M, Jahnsen J, Lygren I. et al. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol 2007; 102: 1955-1963
29 Silvera SA, Rohan TE, Jain M. et al. Glycemic index, glycemic load, and pancreatic cancer risk (Canada). Cancer Causes Control 2005; 16: 431-436
30 Langholz E, Munkholm P, Davidsen M. et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11
31 Henriksen M, Jahnsen J, Lygren I. et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006; 41: 1037-1043
32 Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease--“colitis indeterminate”. J Clin Pathol 1978; 31: 567-577
33 Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn’s disease. Dig Dis Sci 2007; 52: 2063-2068
34 Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665
35 Prantera C, Davoli M, Lorenzetti R. et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10: 41-45
36 Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017-1020
37 Schoepfer AM, Beglinger C, Straumann A. et al. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-1858
38 Mao R, Xiao YL, Gao X. et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894-1899
39 Lin JF, Chen JM, Zuo JH. et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014; 20: 1407-1415
40 Korczowski B, Szybist W. Serum procalcitonin and C-reactive protein in children with diarrhoea of various aetiologies. Acta Paediatr 2004; 93: 169-173
41 Herrlinger KR, Dittmann R, Weitz G. et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 2004; 10: 229-233
42 Mylonaki M, Langmead L, Pantes A. et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775-778
43 Brown WJ, Hudson MJ, Patrick S. et al. Search for enteric microbial pathogens in patients with ulcerative colitis. Digestion 1992; 53: 121-128
44 Bou-Fakhredin R, Halawi R, Roumi J. et al. Insights into the diagnosis and management of iron deficiency in inflammatory bowel disease. Expert Rev Hematol 2017; 1-8
45 Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease – a practical approach. Ann Gastroenterol 2013; 26: 104-113
46 Cappellini MD, Comin-Colet J, de Francisco A. et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;
47 Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599-610
48 Plevy S. Do serological markers and cytokines determine the indeterminate?. J Clin Gastroenterol 2004; 38: S51-S56
49 Riis L, Vind I, Vermeire S. et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007; 13: 24-32
50 Joossens S, Daperno M, Shums Z. et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 2004; 50: 1422-1425
51 Reese GE, Constantinides VA, Simillis C. et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2410-2422
52 Weber P, Koch M, Heizmann WR. et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 302-308
53 Issa M, Vijayapal A, Graham MB. et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351
54 Rodemann JF, Dubberke ER, Reske KA. et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344
55 Johal SS, Hammond J, Solomon K. et al. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004; 53: 673-677
56 Minami M, Ohta M, Ohkura T. et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007; 13: 754-760
57 Matsuoka K, Iwao Y, Mori T. et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 331-337
58 Dimitroulia E, Spanakis N, Konstantinidou AE. et al. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 879-884
59 Hommes DW, Sterringa G, van Deventer SJ. et al. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004; 10: 245-250
60 Poullis A, Foster R, Northfield TC. et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 675-681
61 Langhorst J, Elsenbruch S, Mueller T. et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 1085-1091
62 Menees SB, Powell C, Kurlander J. et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110: 444-454
63 Mosli MH, Zou G, Garg SK. et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110: 802-819
64 D’Inca R, Dal Pont E, Di Leo V. et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008; 103: 2007-2014
65 Costa F, Mumolo MG, Bellini M. et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-647
66 van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369
67 Van de Vijver E, Schreuder AB, Cnossen WR. et al. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 2012; 97: 1014-1018
68 Walker TR, Land ML, Kartashov A. et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 414-422
69 Joishy M, Davies I, Ahmed M. et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 48: 48-54
70 Costa F, Mumolo MG, Ceccarelli L. et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005; 54: 364-368
71 Walkiewicz D, Werlin SL, Fish D. et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 669-673
72 Carbonnel F, Lavergne A, Lemann M. et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 1550-1557
73 Alemayehu G, Jarnerot G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol 1991; 86: 187-190
74 Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005; 3: 11-24
75 Deutsch DE, Olson AD. Colonoscopy or sigmoidoscopy as the initial evaluation of pediatric patients with colitis: a survey of physician behavior and a cost analysis. J Pediatr Gastroenterol Nutr 1997; 25: 26-31
76 Melmed GY, Elashoff R, Chen GC. et al. Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: a nested, case-control study. Clin Gastroenterol Hepatol 2007; 5: 602-608
77 Bryant RV, Burger DC, Delo J. et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016; 65: 408-414
78 Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-1635
79 Shah SC, Colombel JF, Sands BE. et al. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1245-1255.e8
80 Reinink AR, Lee TC, Higgins PD. Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis. Inflamm Bowel Dis 2016; 22: 1859-1869
81 Gisbert JP, Marin AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016; 111: 632-647
82 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629
83 Travis SP, Schnell D, Krzeski P. et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61: 535-542
84 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048
85 Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull 2005; 75-76: 131-144
86 Turner D, Otley AR, Mack D. et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-432
87 Preiss JC, Bokemeyer B, Buhr HJ. et al. [Updated German clinical practice guideline on “Diagnosis and treatment of Crohn’s disease” 2014]. Z Gastroenterol 2014; 52: 1431-1484
88 Parente F, Greco S, Molteni M. et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Aliment Pharmacol Ther 2003; 18: 1009-1016
89 Hollerbach S, Geissler A, Schiegl H. et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. Scand J Gastroenterol 1998; 33: 1201-1208
90 Maconi G, Ardizzone S, Parente F. et al. Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis. Scand J Gastroenterol 1999; 34: 1103-1107
91 Worlicek H, Lutz H, Heyder N. et al. Ultrasound findings in Crohn’s disease and ulcerative colitis: a prospective study. J Clin Ultrasound 1987; 15: 153-163
92 Bozkurt T, Richter F, Lux G. Ultrasonography as a primary diagnostic tool in patients with inflammatory disease and tumors of the small intestine and large bowel. J Clin Ultrasound 1994; 22: 85-91
93 Arienti V, Campieri M, Boriani L. et al. Management of severe ulcerative colitis with the help of high resolution ultrasonography. Am J Gastroenterol 1996; 91: 2163-2169
94 Faure C, Belarbi N, Mougenot JF. et al. Ultrasonographic assessment of inflammatory bowel disease in children: comparison with ileocolonoscopy. J Pediatr 1997; 130: 147-151
95 Pradel JA, David XR, Taourel P. et al. Sonographic assessment of the normal and abnormal bowel wall in nondiverticular ileitis and colitis. Abdom Imaging 1997; 22: 167-172
96 Haber HP, Busch A, Ziebach R. et al. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med 2002; 21: 375-382
97 Pascu M, Roznowski AB, Muller HP. et al. Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging in patients with inflammatory bowel disease of the terminal ileum and large bowel. Inflamm Bowel Dis 2004; 10: 373-382
98 Parente F, Molteni M, Marino B. et al. Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study. Am J Gastroenterol 2009;
99 Ludwig D, Wiener S, Bruning A. et al. Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study. Gut 1999; 45: 546-552
100 Homann N, Klarmann U, Fellermann K. et al. Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn’s disease. Inflamm Bowel Dis 2005; 11: 126-132
101 Girlich C, Schacherer D, Jung EM. et al. Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis. Int J Colorectal Dis 2012; 27: 193-198
102 Rutter MD, Saunders BP, Wilkinson KH. et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-1816
103 Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992; 33: 938-941
104 Reiser JR, Waye JD, Janowitz HD. et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol 1994; 89: 119-122
105 Andersen K, Vogt C, Blondin D. et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur J Radiol 2006; 58: 140-146
106 Horsthuis K, Bipat S, Bennink RJ. et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008; 247: 64-79
107 Fumery M, Pineton de Chambrun G, Stefanescu C. et al. Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clin Gastroenterol Hepatol 2015; 13: 1770-1775
108 Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88: 995-1000
109 Ajaj WM, Lauenstein TC, Pelster G. et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut 2005; 54: 257-263
110 Levine A, Koletzko S, Turner D. et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58: 795-806
111 Allison MC, Hamilton-Dutoit SJ, Dhillon AP. et al. The value of rectal biopsy in distinguishing self-limited colitis from early inflammatory bowel disease. Q J Med 1987; 65: 985-995
112 Bentley E, Jenkins D, Campbell F. et al. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J Clin Pathol 2002; 55: 955-960
113 Dejaco C, Oesterreicher C, Angelberger S. et al. Diagnosing colitis: a prospective study on essential parameters for reaching a diagnosis. Endoscopy 2003; 35: 1004-1008
114 Dube AK, Cross SS, Lobo AJ. Audit of the histopathological diagnosis of non-neoplastic colorectal biopsies: achievable standards for the diagnosis of inflammatory bowel disease. J Clin Pathol 1998; 51: 378-381
115 Dundas SA, Dutton J, Skipworth P. Reliability of rectal biopsy in distinguishing between chronic inflammatory bowel disease and acute self-limiting colitis. Histopathology 1997; 31: 60-66
116 Jenkins D, Balsitis M, Gallivan S. et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50: 93-105
117 Nostrant TT, Kumar NB, Appelman HD. Histopathology differentiates acute self-limited colitis from ulcerative colitis. Gastroenterology 1987; 92: 318-328
118 Schumacher G, Kollberg B, Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. Scand J Gastroenterol 1994; 29: 318-332
119 Seldenrijk CA, Morson BC, Meuwissen SG. et al. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991; 32: 1514-1520
120 Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984; 86: 104-113
121 Tanaka M, Masuda T, Yao T. et al. Observer variation of diagnoses based on simple biopsy criteria differentiating among Crohn’s disease, ulcerative colitis, and other forms of colitis. J Gastroenterol Hepatol 2001; 16: 1368-1372
122 Tanaka M, Riddell RH, Saito H. et al. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn’s disease from ulcerative colitis. Scand J Gastroenterol 1999; 34: 55-67
123 Tanaka M, Saito H, Fukuda S. et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol 2000; 35: 281-286
124 Theodossi A, Spiegelhalter DJ, Jass J. et al. Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. Gut 1994; 35: 961-968
125 McHugh JB, Appelman HD, McKenna BJ. The diagnostic value of endoscopic terminal ileum biopsies. Am J Gastroenterol 2007; 102: 1084-1089
126 Cherian S, Singh P. Is routine ileoscopy useful? An observational study of procedure times, diagnostic yield, and learning curve. Am J Gastroenterol 2004; 99: 2324-2329
127 Geboes K, Ectors N, D’Haens G. et al. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease?. Am J Gastroenterol 1998; 93: 201-206
128 Lemberg DA, Clarkson CM, Bohane TD. et al. Role of esophagogastroduodenoscopy in the initial assessment of children with inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1696-1700
129 Surawicz CM. Serial sectioning of a portion of a rectal biopsy detects more focal abnormalities: a prospective study of patients with inflammatory bowel disease. Dig Dis Sci 1982; 27: 434-436
130 Surawicz CM, Meisel JL, Ylvisaker T. et al. Rectal biopsy in the diagnosis of Crohn’s disease: value of multiple biopsies and serial sectioning. Gastroenterology 1981; 80: 66-71
131 Therkildsen MH, Jensen BN, Teglbjaerg PS. et al. The final outcome of patients presenting with their first episode of acute diarrhoea and an inflamed rectal mucosa with preserved crypt architecture. A clinicopathologic study. Scand J Gastroenterol 1989; 24: 158-164
132 Washington K, Greenson JK, Montgomery E. et al. Histopathology of ulcerative colitis in initial rectal biopsy in children. Am J Surg Pathol 2002; 26: 1441-1449
133 Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50 (Suppl. 03) III37-III42
134 Odze R, Antonioli D, Peppercorn M. et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17: 869-875
135 Kleer CG, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 1998; 22: 983-989
136 North American Society for Pediatric Gastroenterology H, Nutrition, Colitis Foundation of A. et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653-674
137 Glickman JN, Bousvaros A, Farraye FA. et al. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am J Surg Pathol 2004; 28: 190-197
138 Robert ME, Tang L, Hao LM. et al. Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences in pediatric populations are limited to children younger than 10 years. Am J Surg Pathol 2004; 28: 183-189
139 Markowitz J, Kahn E, Grancher K. et al. Atypical rectosigmoid histology in children with newly diagnosed ulcerative colitis. Am J Gastroenterol 1993; 88: 2034-2037
140 Autschbach F, Hoffmann JCKA, Klump B. eds. Chronisch entzündliche Darmerkrankungen Das CED-Handbuch für Klinik und Praxis. Stuttgart: Thieme; 2004: 110-122
141 Borchard F. [Differential diagnosis of colitis]. Verh Dtsch Ges Pathol 1999; 83: 110-121
142 A vH. Histopathologische Diagnostik chronischentzündlicher Darmerkrankungen. Historischer Rückblick und aktuelle Übersicht. Pathologe 1999 1999; 20: 276-287
143 Gomes P, du Boulay C, Smith CL. et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-95
144 D’Haens G, Van Deventer S, Van Hogezand R. et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034
145 Riley SA, Mani V, Goodman MJ. et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991; 32: 174-178
146 Bitton A, Peppercorn MA, Antonioli DA. et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20
147 Nishio Y, Ando T, Maeda O. et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006; 55: 1768-1773
148 Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C. et al. Development and validation of the Nancy histological index for UC. Gut 2017; 66: 43-49
149 Mosli MH, Feagan BG, Zou G. et al. Development and validation of a histological index for UC. Gut 2017; 66: 50-58
150 Riddell RH, Goldman H, Ransohoff DF. et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-68
151 Goldman H. Significance and detection of dysplasia in chronic colitis. Cancer 1996; 78: 2261-2263
152 Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000; 47: 57-70
153 Melville DM, Jass JR, Morson BC. et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989; 20: 1008-1014
154 Eaden J, Abrams K, McKay H. et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001; 194: 152-157
155 Odze RD, Goldblum J, Noffsinger A. et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002; 15: 379-386
156 Dignass A, Eliakim R, Magro F. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-990
157 Magro F, Gionchetti P, Eliakim R. et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017; 11: 649-670
158 Laine L, Kaltenbach T, Barkun A. et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 489-501 e26
159 Farraye FA, Odze RD, Eaden J. et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-745
160 Rutter MD, Saunders BP, Wilkinson KH. et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004; 60: 334-339
161 Blackstone MO, Riddell RH, Rogers BH. et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981; 80: 366-374
162 Lennard-Jones JE, Melville DM, Morson BC. et al. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990; 31: 800-806
163 Butt JH, Konishi F, Morson BC. et al. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis. Dig Dis Sci 1983; 28: 18-26
164 Jonsson B, Ahsgren L, Andersson LO. et al. Colorectal cancer surveillance in patients with ulcerative colitis. Br J Surg 1994; 81: 689-691
165 Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991; 100: 1241-1248
166 Lofberg R, Brostrom O, Karlen P. et al. Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. Gastroenterology 1990; 99: 1021-1031
167 Eaden J, Abrams K, Ekbom A. et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153
168 Rosenstock E, Farmer RG, Petras R. et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985; 89: 1342-1346
169 Karlen P, Kornfeld D, Brostrom O. et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-714
170 Lashner BA, Turner BC, Bostwick DG. et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990; 35: 349-352
171 Choi PM, Nugent FW, Schoetz Jr. DJ. et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-424
172 Collins PD, Mpofu C, Watson AJ. et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; CD000279
173 Winther KV, Jess T, Langholz E. et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1088-1095
174 Lutgens MW, Vleggaar FP, Schipper ME. et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-1251
175 Lutgens MW, Oldenburg B, Siersema PD. et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 2009; 101: 1671-1675
176 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535
177 Lakatos L, Mester G, Erdelyi Z. et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-211
178 Soderlund S, Brandt L, Lapidus A. et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136: 1561-1567
179 Gupta RB, Harpaz N, Itzkowitz S. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105
180 Jess T, Loftus Jr. EV, Velayos FS. et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130: 1039-1046
181 Rutter MD, Saunders BP, Wilkinson KH. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038
182 Velayos FS, Loftus Jr. EV, Jess T. et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006; 130: 1941-1949
183 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645
184 Jess T, Horvath-Puho E, Fallingborg J. et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013; 108: 1869-1876
185 Choi CH, Rutter MD, Askari A. et al. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. Am J Gastroenterol 2015; 110: 1022-1034
186 Selinger CP, Andrews JM, Titman A. et al. Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12: 644-650
187 Annese V, Daperno M, Rutter MD. et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018
188 Thomas-Gibson S, Rogers P, Cooper S. et al. Judgement of the quality of bowel preparation at screening flexible sigmoidoscopy is associated with variability in adenoma detection rates. Endoscopy 2006; 38: 456-460
189 Toruner M, Harewood GC, Loftus Jr. EV. et al. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 428-434
190 Van Assche G, Dignass A, Bokemeyer B. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33
191 Rutter M, Saunders B, Wilkinson K. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459
192 Claessen MM, Lutgens MW, van Buuren HR. et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-1336
193 Cairns SR, Scholefield JH, Steele RJ. et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689
194 Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 1994; 343: 71-74
195 Befrits R, Ljung T, Jaramillo E. et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002; 45: 615-620
196 Leidenius M, Kellokumpu I, Husa A. et al. Dysplasia and carcinoma in longstanding ulcerative colitis: an endoscopic and histological surveillance programme. Gut 1991; 32: 1521-1525
197 Jess T, Loftus Jr. EV, Velayos FS. et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 2006; 12: 669-676
198 Thomas T, Abrams KA, Robinson RJ. et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 657-668
199 Lim CH, Dixon MF, Vail A. et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127-1132
200 Heuschen UA, Hinz U, Allemeyer EH. et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-847
201 Moussata D, Allez M, Cazals-Hatem D. et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?. Gut 2018; 67: 616-624
202 Hlavaty T, Huorka M, Koller T. et al. Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 2011; 23: 680-689
203 Kiesslich R, Fritsch J, Holtmann M. et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888
204 Hurlstone DP, Sanders DS, Lobo AJ. et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005; 37: 1186-1192
205 Kiesslich R, Goetz M, Lammersdorf K. et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007; 132: 874-882
206 Subramanian V, Mannath J, Ragunath K. et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 304-312
207 Wu L, Li P, Wu J. et al. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 2012; 14: 416-420
208 Carballal S, Maisterra S, Lopez-Serrano A. et al. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 2016;
209 Iannone A, Ruospo M, Wong G. et al. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn’s Disease: A Systematic Review of Randomized Trials. Clin Gastroenterol Hepatol 2016;
210 Gasia MF, Ghosh S, Panaccione R. et al. Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. Clin Gastroenterol Hepatol 2016; 14: 704-712 e4
211 Watanabe T, Ajioka Y, Mitsuyama K. et al. Comparison of Targeted vs. Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 2016; 151: 1122-1130
212 Moussata D, Allez M, Cazals-Hatem D. et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?. Gut 2017;
213 Subramanian V, Ramappa V, Telakis E. et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 350-355
214 Iannone A, Ruospo M, Wong G. et al. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn’s Disease: A Systematic Review of Randomized Trials. Clin Gastroenterol Hepatol 2017; 15: 1684-1697 e11
215 Dekker E, van den Broek FJ, Reitsma JB. et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007; 39: 216-221
216 Ignjatovic A, East JE, Subramanian V. et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol 2012; 107: 885-890
217 Pellise M, Lopez-Ceron M, Rodriguez de Miguel C. et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc 2011; 74: 840-848
218 Gunther U, Kusch D, Heller F. et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis 2011; 26: 667-672
219 van den Broek FJ, van Es JA, van Eeden S. et al. Pilot study of probe-based confocal laser endomicroscopy during colonoscopic surveillance of patients with longstanding ulcerative colitis. Endoscopy 2011; 43: 116-122
220 Bisschops R, Bessissow T, Joseph JA. et al. Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. Gut 2017;
221 Leifeld L, Rogler G, Stallmach A. et al. White-Light or Narrow-Band Imaging Colonoscopy in Surveillance of Ulcerative Colitis: A Prospective Multicenter Study. Clin Gastroenterol Hepatol 2015; 13: 1776-1781 e1
222 Omata F, Ohde S, Deshpande GA. et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand J Gastroenterol 2014; 49: 222-237
223 Taylor BA, Pemberton JH, Carpenter HA. et al. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum 1992; 35: 950-956
224 Fumery M, Dulai PS, Gupta S. et al. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 665-674 e5
225 Ullman T, Croog V, Harpaz N. et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-1319
226 Rubin PH, Friedman S, Harpaz N. et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117: 1295-1300
227 Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut 2006; 55: 1151-1155
228 Odze RD, Farraye FA, Hecht JL. et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004; 2: 534-541
229 Wanders LK, Dekker E, Pullens B. et al. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 756-764
230 Pardi DS, Loftus Jr. EV, Kremers WK. et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893
231 Tung BY, Emond MJ, Haggitt RC. et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95
232 Lindor KD, Kowdley KV, Luketic VA. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814
233 LeBlanc K, Mosli MH, Parker CE. et al. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev 2015; CD008655
234 Ford AC, Achkar JP, Khan KJ. et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-616
235 Timmer A, Patton PH, Chande N. et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; CD000478
236 Colombel JF, Rutgeerts P, Reinisch W. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
237 Marshall JK, Thabane M, Steinhart AH. et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; CD004115
238 Lie MR, Kanis SL, Hansen BE. et al. Drug therapies for ulcerative proctitis: systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 2157-2178
239 Cohen RD, Dalal SR. Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. Inflamm Bowel Dis 2015; 21: 1719-1736
240 Romkens TE, Kampschreur MT, Drenth JP. et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18: 2190-2198
241 Andus T, Kocjan A, Muser M. et al. Clinical trial: a novel high-dose 1g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010; 16: 1947-1956
242 Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011; 56: 513-522
243 Gionchetti P, Rizzello F, Venturi A. et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998; 41: 93-97
244 Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-781
245 Regueiro M, Loftus Jr. EV, Steinhart AH. et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006; 12: 979-994
246 Mulder CJ, Fockens P, Meijer JW. et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3 mg/2g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8: 549-553
247 Sandborn WJ, Bosworth B, Zakko S. et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015; 148: 740-750 e2
248 Bosworth BP, Sandborn WJ, Rubin DT. et al. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis 2016; 22: 1881-1886
249 Leifeld L, Pfutzer R, Morgenstern J. et al. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis. Aliment Pharmacol Ther 2011; 34: 1115-1122
250 Benson A, Barrett T, Sparberg M. et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12
251 Lawrance IC, Baird A, Lightower D. et al. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clin Gastroenterol Hepatol 2017; 15: 1248-1255
252 Ford AC, Khan KJ, Achkar JP. et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 167-176
253 Pimpo MT, Galletti B, Palumbo G. et al. Mesalazine vanishing time from rectal mucosa following its topical administration. J Crohns Colitis 2010; 4: 102-105
254 Cortot A, Maetz D, Degoutte E. et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008; 103: 3106-3114
255 Wang Y, Parker CE, Bhanji T. et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 4: CD000543
256 Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflamm Bowel Dis 2013; 19: 2031-2040
257 Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 21-29
258 Severs M, Mangen MJ, Fidder HH. et al. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23: 1568-1576
259 Flourie B, Hagege H, Tucat G. et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013; 37: 767-775
260 Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18: 1785-1794
261 Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis – new light on a familiar question. Aliment Pharmacol Ther 2011; 33: 1028-1035
262 Sherlock ME, Seow CH, Steinhart AH. et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; CD007698
263 Sandborn WJ, Travis S, Moro L. et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-1226 e1-2
264 Travis SP, Danese S, Kupcinskas L. et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-441
265 Sandborn WJ, Danese S, D’Haens G. et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther 2015; 41: 409-418
266 Sherlock ME, MacDonald JK, Griffiths AM. et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015; CD007698
267 Marshall JK, Thabane M, Steinhart AH. et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 11: CD004118
268 Moody GA, Eaden JA, Helyes Z. et al. Oral or rectal administration of drugs in IBD?. Aliment Pharmacol Ther 1997; 11: 999-1000
269 Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opin Pharmacother 2016; 17: 1339-1349
270 Losurdo G, Iannone A, Contaldo A. et al. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2015; 24: 499-505
271 Scaldaferri F, Gerardi V, Mangiola F. et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol 2016; 22: 5505-5511
272 d’Albasio G, Pacini F, Camarri E. et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-1147
273 Yokoyama H, Takagi S, Kuriyama S. et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-1120
274 Piodi LP, Ulivieri FM, Cermesoni L. et al. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004; 39: 154-157
275 Bokemeyer B, Hommes D, Gill I. et al. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohns Colitis 2012; 6: 476-482
276 Kamm MA, Lichtenstein GR, Sandborn WJ. et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902
277 Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544
278 Dignass AU, Bokemeyer B, Adamek H. et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-769
279 Gordon GL, Zakko S, Murthy U. et al. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. J Clin Gastroenterol 2016; 50: 318-325
280 Kruis W, Jonaitis L, Pokrotnieks J. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-322
281 Sandborn WJ, Korzenik J, Lashner B. et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138: 1286-1296
282 Heyman MB, Kierkus J, Spenard J. et al. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis 2010; 16: 1931-1939
283 Kobayashi K, Hirai F, Naganuma M. et al. A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. J Crohns Colitis 2014; 8: 1444-1453
284 Watanabe M, Nishino H, Sameshima Y. et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo-controlled study. Aliment Pharmacol Ther 2013; 38: 264-273
285 Kruis W, Jonaitis L, Pokrotnieks J. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-322
286 Yokoyama H, Takagi S, Kuriyama S. et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-1120
287 Ardizzone S, Porro GB. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?. Inflamm Bowel Dis 2008; 14 (Suppl. 02) S238-S239
288 Heap GA, So K, Weedon M. et al. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 149-158
289 Zallot C, Billioud V, Frimat L. et al. 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. J Crohns Colitis 2013; 7: 551-555
290 Nikolaus S, Schreiber S, Siegmund B. et al. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. J Crohns Colitis 2017; 11: 1052-1062
291 Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353
292 Biancone L, Michetti P, Travis S. et al. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008; 2: 63-92
293 Rubin DT, Huo D, Kinnucan JA. et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013; 11: 1601-1608 e1-4
294 Mathy C, Schneider K, Chen YY. et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003; 9: 351-355
295 Choi CH, Ignjatovic-Wilson A, Askari A. et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol 2015; 110: 1461-1471
296 Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 77-85
297 Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004; 126: 1634-1648
298 Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010; 31: 202-209
299 Ullman T, Croog V, Harpaz N. et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol 2008; 6: 1225-1230
300 Bergeron VN-LI, Vienne A, Seksik P. et al. Azathioprine [AZA] is associated with less histological inflammation of the colon in inactive IBD. Gastroenterology 2010; 138: 693
301 Lashner BA, Provencher KS, Seidner DL. et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32
302 Terdiman JP, Steinbuch M, Blumentals WA. et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 367-371
303 Matula S, Croog V, Itzkowitz S. et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005; 3: 1015-1021
304 van Schaik FD, van Oijen MG, Smeets HM. et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61: 235-240
305 Beaugerie L, Svrcek M, Seksik P. et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145: 166-175 e8
306 Lindgren S, Lofberg R, Bergholm L. et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002; 37: 705-710
307 Meyers S, Lerer PK, Feuer EJ. et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987; 9: 50-54
308 Lichtenstein GR, Feagan BG, Cohen RD. et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107: 1409-1422
309 Edwards FC, Truelove SC. The Course and Prognosis of Ulcerative Colitis. Gut 1963; 4: 299-315
310 Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut 2011; 60: 130-133
311 Turner D, Walsh CM, Steinhart AH. et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110
312 Lynch RW, Lowe D, Protheroe A. et al. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 2013; 38: 935-945
313 Baron JH, Connell AM, Kanaghinis TG. et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2: 441-443
314 Lennard-Jones JE, Longmore AJ, Newell AC. et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217-222
315 Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-1070
316 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-378
317 Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959; 1: 387-394
318 Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990; 12: 40-41
319 Bartels SA, Gardenbroek TJ, Bos L. et al. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis. Colorectal Dis 2013; 15: 1392-1398
320 Bernstein CN, Ng SC, Lakatos PL. et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001-2010
321 Randall J, Singh B, Warren BF. et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010; 97: 404-409
322 Roberts SE, Williams JG, Yeates D. et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. BMJ 2007; 335: 1033
323 Dignass AU, Gasche C, Bettenworth D. et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211-222
324 Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012; 18: 584-591
325 Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003; 98: 2363-2371
326 Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 255-263
327 Long MD, Barnes EL, Herfarth HH. et al. Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm Bowel Dis 2012; 18: 869-876
328 Domenech E, Vega R, Ojanguren I. et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008; 14: 1373-1379
329 Kishore J, Ghoshal U, Ghoshal UC. et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004; 53: 1155-1160
330 Lee HS, Park SH, Kim SH. et al. Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2016; 22: 912-918
331 Papadakis KA, Tung JK, Binder SW. et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2137-2142
332 Rahier JF, Magro F, Abreu C. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-468
333 Siegmund B. Cytomegalovirus infection associated with inflammatory bowel disease. Lancet Gastroenterol Hepatol 2017; 2: 369-376
334 Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 2013; 19: 194-204
335 Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-1442
336 Jen MH, Saxena S, Bottle A. et al. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-1331
337 Murthy SK, Steinhart AH, Tinmouth J. et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012; 36: 1032-1039
338 Negron ME, Barkema HW, Rioux K. et al. Clostridium difficile infection worsens the prognosis of ulcerative colitis. Can J Gastroenterol Hepatol 2014; 28: 373-380
339 Nguyen GC, Kaplan GG, Harris ML. et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-1450
340 Hagel S, Epple HJ, Feurle GE. et al. [S2k-guideline gastrointestinal infectious diseases and Whipple’s disease]. Z Gastroenterol 2015; 53: 418-459
341 Ben-Horin S, Margalit M, Bossuyt P. et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-987
342 Rahier JF, Ben-Horin S, Chowers Y. et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91
343 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663
344 Harbord M, Annese V, Vavricka SR. et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 239-254
345 Kappelman MD, Horvath-Puho E, Sandler RS. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-943
346 Nguyen GC, Bernstein CN, Bitton A. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146: 835-848 e6
347 Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M. et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88: 227-232
348 McIntyre PB, Powell-Tuck J, Wood SR. et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27: 481-485
349 Turner D, Travis SP, Griffiths AM. et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106: 574-588
350 Lindgren SC, Flood LM, Kilander AF. et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-835
351 Llao J, Naves JE, Ruiz-Cerulla A. et al. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. J Crohns Colitis 2014; 8: 1523-1528
352 Sands BE, Peyrin-Biroulet L, Loftus EV. et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine 2019; 381: 1215-1226
353 Burr NE, Gracie DJ, Black CJ. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021;
354 Lasa JS, Olivera PA, Danese S. et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology 2022; 7: 161-170
355 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
356 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265 e1-3
357 Sandborn WJ, Feagan BG, Marano C. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95
358 Sandborn WJ, Feagan BG, Marano C. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109 e1
359 Sandborn WJ, Su C, Sands BE. et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine 2017; 376: 1723-1736
360 Panés J, Vermeire S, Lindsay JO. et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. Journal of Crohn’s and Colitis 2018; 13: 139-140
361 Feagan BG, Danese S, Loftus Jr. EV. et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. The Lancet 2021; 397: 2372-2384
362 Danese S, Vermeire S, Zhou W. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022; 399: 2113-2128
363 Olivera PA, Lasa JS, Zubiaurre I. et al. Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis 2023; 17: 199-210
364 Ytterberg SR, Bhatt DL, Mikuls TR. et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386: 316-326
365 Solitano V, Vuyyuru SK, MacDonald JK. et al. Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis. J Crohns Colitis 2023;
366 Sands BE, Sandborn WJ, Panaccione R. et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019; 381: 1201-1214
367 D’Haens G, Dubinsky M, Kobayashi T. et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388: 2444-2455
368 Sandborn WJ, Feagan BG, D’Haens G. et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine 2021; 385: 1280-1291
369 Sandborn WJ, Feagan BG, Hanauer S. et al. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn’s and Colitis 2021; 15: 1120-1129
370 Lennard-Jones JE, Ritchie JK, Hilder W. et al. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579-584
371 Travis SP, Farrant JM, Ricketts C. et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910
372 Benazzato L, D’Inca R, Grigoletto F. et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 36: 461-466
373 Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut 1991; 32: 1535-1537
374 Carbonnel F, Gargouri D, Lemann M. et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-279
375 Corte C, Fernandopulle N, Catuneanu AM. et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015; 9: 376-381
376 Ho GT, Mowat C, Goddard CJ. et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-1087
377 Kato K, Ohkusa T, Terao S. et al. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther 2014; 39: 949-956
378 Mantzaris GJ, Hatzis A, Kontogiannis P. et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46
379 Lichtiger S, Present DH, Kornbluth A. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
380 D’Haens G, Lemmens L, Geboes K. et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329
381 Van Assche G, D’Haens G, Noman M. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031
382 Laharie D, Bourreille A, Branche J. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
383 Williams JG, Alam MF, Alrubaiy L. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2016; 1: 15-24
384 Shibolet O, Regushevskaya E, Brezis M. et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; CD004277
385 Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592
386 Moskovitz DN, Van Assche G, Maenhout B. et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-765
387 Bamba S, Tsujikawa T, Inatomi O. et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 494-498
388 Walch A, Meshkat M, Vogelsang H. et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010; 4: 398-404
389 Cheifetz AS, Stern J, Garud S. et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol 2011; 45: 107-112
390 Ogata H, Matsui T, Nakamura M. et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262
391 Ogata H, Kato J, Hirai F. et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-808
392 Komaki Y, Komaki F, Ido A. et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis 2016; 10: 484-494
393 Schmidt KJ, Herrlinger KR, Emmrich J. et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis – experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-136
394 Yamamoto T, Shimoyama T, Umegae S. et al. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. Aliment Pharmacol Ther 2016; 43: 705-716
395 Jarnerot G, Hertervig E, Friis-Liby I. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811
396 Gustavsson A, Jarnerot G, Hertervig E. et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32: 984-989
397 Sjoberg M, Magnuson A, Bjork J. et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38: 377-387
398 Monterubbianesi R, Aratari A, Armuzzi A. et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 2014; 8: 852-858
399 Mortensen C, Caspersen S, Christensen NL. et al. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis 2011; 5: 28-33
400 Brandse JF, Mathot RA, van der Kleij D. et al. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2016; 14: 251-258 e1-2
401 Brandse JF, van den Brink GR, Wildenberg ME. et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015; 149: 350-355 e2
402 Gibson DJ, Heetun ZS, Redmond CE. et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335 e1
403 Armuzzi A, Pugliese D, Danese S. et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014; 20: 1368-1374
404 Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013; 28: 287-293
405 Lowenberg M, Duijvis NW, Ponsioen C. et al. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis. Eur J Gastroenterol Hepatol 2014; 26: 1240-1246
406 Hyde GM, Jewell DP, Kettlewell MG. et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44: 1436-1440
407 Ferrante M, D’Hoore A, Vermeire S. et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1062-1070
408 Narula N, Fine M, Colombel JF. et al. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?. Inflamm Bowel Dis 2015; 21: 1683-1694
409 Hebden JM, Blackshaw PE, Perkins AC. et al. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 155-161
410 Nel JA. [Management of patients with AMS 800 urinary artificial sphincter]. Nurs RSA 1991; 6: 28-32
411 Sandborn WJ, Tremaine WJ, Schroeder KW. et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106: 1429-1435
412 Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996; 41: 2254-2259
413 van Dieren JM, van Bodegraven AA, Kuipers EJ. et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009; 15: 193-198
414 Carbonnel F, Boruchowicz A, Duclos B. et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 2471-2476
415 Actis GC, Fadda M, David E. et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007; 7: 13
416 Szanto K, Molnar T, Farkas K. New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab. J Crohns Colitis 2017;
417 Sandborn WJ, Panes J, D’Haens GR. et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol 2018;
418 Ardizzone S, Maconi G, Russo A. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
419 Chebli LA, Chaves LD, Pimentel FF. et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010; 16: 613-619
420 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400 e3
421 Singh S, Fumery M, Sandborn WJ. et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 162-175
422 Bonovas S, Lytras T, Nikolopoulos G. et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454-465
423 Feagan BG, Rutgeerts P, Sands BE. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
424 Sands BE, Peyrin-Biroulet L, Loftus Jr. EV. et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019; 381: 1215-1226
425 Carbonnel F, Colombel JF, Filippi J. et al. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology 2016; 150: 380-388 e4
426 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; CD005112
427 Reinisch W, Sandborn WJ, Hommes DW. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787
428 Reinisch W, Sandborn WJ, Panaccione R. et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19: 1700-1709
429 Gies N, Kroeker KI, Wong K. et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 522-528
430 Colombel JF, Sandborn WJ, Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
431 van Schaik T, Maljaars JP, Roopram RK. et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis 2014; 20: 2292-2298
432 Yamamoto S, Nakase H, Mikami S. et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-597
433 Gisbert JP, Marin AC, McNicholl AG. et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41: 613-623
434 Baumgart DC, Bokemeyer B, Drabik A. et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090-1102
435 Sandborn WS, D’Haens G. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology 2016; 150 (04) S157
436 Yoo DH, Hrycaj P, Miranda P. et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-1620
437 Park W, Hrycaj P, Jeka S. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-1612
438 Jorgensen KK, Olsen IC, Goll GL. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389: 2304-2316
439 Hawthorne AB, Logan RF, Hawkey CJ. et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22
440 Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630
441 Sood A, Kaushal V, Midha V. et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-274
442 Sood A, Midha V, Sood N. et al. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003; 22: 79-81
443 Mate-Jimenez J, Hermida C, Cantero-Perona J. et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-1233
444 Cassinotti A, Actis GC, Duca P. et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-2767
445 George J, Present DH, Pou R. et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-1714
446 Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
447 Ardizzone S, Molteni P, Imbesi V. et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25: 330-333
448 Lobo AJ, Foster PN, Burke DA. et al. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990; 33: 374-377
449 Khan ZH, Mayberry JF, Spiers N. et al. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 249-254
450 Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 717-722
451 Moreno-Rincon E, Benitez JM, Serrano-Ruiz FJ. et al. Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal. Inflamm Bowel Dis 2015; 21: 1564-1571
452 Fernandez-Banares F, Bertran X, Esteve-Comas M. et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498-2499
453 Ferrante M, Vermeire S, Fidder H. et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-225
454 Feagan BG, Sandborn WJ, Lazar A. et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014; 146: 110-118 e3
455 Colombel JF, Sandborn WJ, Ghosh S. et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014; 109: 1771-1780
456 Loftus Jr. EV, Colombel JF, Feagan BG. et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis 2017; 11: 400-411
457 Feagan BG, Rubin DT, Danese S. et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol 2017; 15: 229-239 e5
458 Noman M, Ferrante M, Bisschops R. et al. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis. J Crohns Colitis 2017; 11: 1085-1089
459 Stallmach A, Langbein C, Atreya R. et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Aliment Pharmacol Ther 2016; 44: 1199-1212
460 Amiot A, Serrero M, Peyrin-Biroulet L. et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther 2017; 46: 310-321
461 Bickston SJ, Behm BW, Tsoulis DJ. et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2014; CD007571
462 Ungar B, Kopylov U, Engel T. et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2017; 45: 276-282
463 Matsumoto T, Motoya S, Watanabe K. et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial. J Crohns Colitis 2016; 10: 1259-1266
464 Oren R, Arber N, Odes S. et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-1421
465 Wahed M, Louis-Auguste JR, Baxter LM. et al. Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009; 30: 614-620
466 Wang Y, MacDonald JK, Vandermeer B. et al. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2015; CD007560
467 Torres J, Boyapati RK, Kennedy NA. et al. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 2015; 149: 1716-1730
468 Marits P, Landucci L, Sundin U. et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014; 8: 881-889
469 Mazor Y, Almog R, Kopylov U. et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther 2014; 40: 620-628
470 Cornillie F, Hanauer SB, Diamond RH. et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-1727
471 Pouw MF, Krieckaert CL, Nurmohamed MT. et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015; 74: 513-518
472 Seow CH, Newman A, Irwin SP. et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54
473 Moore C, Corbett G, Moss AC. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 619-625
474 Roblin X, Marotte H, Rinaudo M. et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-84 e2
475 Harzallah I, Rigaill J, Williet N. et al. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol 2017; 10: 89-100
476 Afif W, Loftus Jr. EV, Faubion WA. et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-1139
477 Frederiksen MT, Ainsworth MA, Brynskov J. et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014; 20: 1714-1721
478 O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 1-6
479 Ungar B, Chowers Y, Yavzori M. et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63: 1258-1264
480 Steenholdt C, Al-khalaf M, Brynskov J. et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2209-2217
481 Yanai H, Lichtenstein L, Assa A. et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015; 13: 522-530 e2
482 Yacoub W, Williet N, Pouillon L. et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther 2018; 47: 906-912
483 Schulze H, Esters P, Hartmann F. et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol 2018; 1-7
484 Dreesen E, Verstockt B, Bian S. et al. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2018;
485 Baumgart DC, Pintoffl JP, Sturm A. et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-1056
486 Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41: 1227-1236
487 Brassard P, Bitton A, Suissa A. et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol 2014; 109: 1795-1802
488 Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-963
489 Dixon WG, Kezouh A, Bernatsky S. et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011; 70: 956-960
490 Jick SS, Lieberman ES, Rahman MU. et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 19-26
491 Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013; 7: 107-112
492 Ha CY. Risks of Infection among the Older Inflammatory Bowel Disease Patients. Curr Treat Options Gastroenterol 2014; 12: 283-291
493 Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31: 578-585
494 Strangfeld A, Eveslage M, Schneider M. et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70: 1914-1920
495 Ananthakrishnan AN, Cagan A, Cai T. et al. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2015; 41: 1141-1148
496 Blum HE, Berg T, Tillmann HL. et al. [Procedures for problematic situations with hepatitis B]. Z Gastroenterol 2004; 42: 692-697
497 Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228
498 Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076-1081
499 Esteve M, Saro C, Gonzalez-Huix F. et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365
500 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2: 152-162
501 Cornberg M, Protzer U, Petersen J. et al. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline]. Z Gastroenterol 2011; 49: 871-930
502 Diel R, Forssbohm M, Loytved G. et al. Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose. Pneumologie 2007; 61: 440-455
503 Schoepfer AM, Flogerzi B, Fallegger S. et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2799-2806
504 Hatzara C, Hadziyannis E, Kandili A. et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 2015; 74: 1848-1853
505 Thorley-Lawson DA. EBV the prototypical human tumor virus--just how bad is it?. J Allergy Clin Immunol 2005; 116: 251-261
506 Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-821
507 Funch DP, Walker AM, Schneider G. et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900
508 Reddy N, Rezvani K, Barrett AJ. et al. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17: 591-597
509 Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol 2013; 6: 43-49
510 Teich N, Klugmann T, Tiedemann A. et al. Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int 2011; 108: 105-111
511 Borte S, Liebert UG, Borte M. et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009; 48: 144-148
512 Nguyen DL, Nguyen ET, Bechtold ML. Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis. Dig Dis Sci 2015; 60: 2446-2453
513 Poppers DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflamm Bowel Dis 2008; 14: 106-113
514 Cotter TG, Gathaiya N, Catania J. et al. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol 2017; 15: 850-856
515 Long MD, Farraye FA, Okafor PN. et al. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1018-1024
516 Stern A, Green H, Paul M. et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014; CD005590
517 Messiaen PE, Cuyx S, Dejagere T. et al. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review. Transpl Infect Dis 2017; 19
518 Ioannidis JP, Cappelleri JC, Skolnik PR. et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156: 177-188
519 Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis 2002; 8: 213-218
520 Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-210
521 Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease. Am J Gastroenterol 2010; 105: 2040-2049
522 Schneeweiss S, Korzenik J, Solomon DH. et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-264
523 Singh H, Nugent Z, Yu BN. et al. Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology 2017; 153: 430-438 e2
524 Dallal RM, Harbrecht BG, Boujoukas AJ. et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372
525 Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 2006; 44: 2785-2791
526 Crobach MJ, Planche T, Eckert C. et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016; 22 (Suppl. 04) S63-S81
527 von Müller L, Halfmann A, Herrmann M. [Current data and trends on the development of antibiotic resistance of Clostridium difficile]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 1410-1417
528 Erb S, Frei R, Stranden AM. et al. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. Clin Microbiol Infect 2015; 21: 998 e9-998 e15
529 Vonberg RP, Kuijper EJ, Wilcox MH. et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 (Suppl. 05) 2-20
530 McDonald LC, Gerding DN, Johnson S. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: e1-e48
531 Fekety R, Silva J, Kauffman C. et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 15-19
532 Horton HA, Dezfoli S, Berel D. et al. Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease. Antimicrob Agents Chemother 2014; 58: 5054-5059
533 Louie TJ, Miller MA, Mullane KM. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431
534 Crook DW, Walker AS, Kean Y. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 (Suppl. 02) S93-S103
535 Al Momani LA, Abughanimeh O, Boonpheng B. et al. Fidaxomicin vs. Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review. Cureus 2018; 10: e2778
536 Hogenauer C, Mahida Y, Stallmach A. et al. Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE). J Antimicrob Chemother 2018; 73: 3430-3441
537 Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; 3: CD004610
538 Aziz M, Desai M, Fatima R. et al. Surotomycin (a novel cyclic lipopeptide) vs. Vancomycin for treatment of Clostridioides difficile infection: A systematic review and Meta-analysis. Curr Clin Pharmacol 2019;
539 Gerding DN, Cornely OA, Grill S. et al. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis 2019; 19: 265-274
540 Shen NT, Maw A, Tmanova LL. et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology 2017; 152: 1889-1900 e9
541 Wilcox MH, Gerding DN, Poxton IR. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017; 376: 305-317
542 Kelly CP, Wilcox MH, Glerup H. et al. Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease. Gastroenterology 2018; 155: 1270-1271
543 Stallmach A, Reuken PA, Teich N. Aktuelle Konzepte zur Diagnostik und Therapie der Clostridioides [Clostridium]-difficile-Infektion bei Patienten mit chronisch-entzündlichen Darmerkrankungen. Z Gastroenterol 2018; 56: 1369-1377
544 Gerding DN, Muto CA, Owens RC. et al. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl. 01) S32-S42
545 McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775
546 Eiseman B, Silen W, Bascom GS. et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-859
547 van Nood E, Vrieze A, Nieuwdorp M. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415
548 Hvas CL, Dahl Jørgensen SM, Jørgensen SP. et al. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology 2019; 156: 1324-1332.e3
549 Lai CY, Sung J, Cheng F. et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther 2019; 49: 354-363
550 Tariq R, Pardi DS, Bartlett MG. et al. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. Clin Infect Dis 2019; 68: 1351-1358
551 Fischer M, Kao D, Kelly C. et al. Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22: 2402-2409
552 Khoruts A, Rank KM, Newman KM. et al. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clin Gastroenterol Hepatol 2016; 14: 1433-1438
553 Teich N, Weber M, Stallmach A. First Occurrence of Severe Extraintestinal Manifestations of Crohn’s Disease Following Faecal Microbiota Transplantation. J Crohns Colitis 2016; 10: 1254-1255
554 Beaugerie L, Brousse N, Bouvier AM. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625
555 Posthuma EF, Westendorp RG, van der Sluys Veer A. et al. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut 1995; 36: 311-313
556 Garrido Serrano A, Perez Martin F, Guerrero Igea FJ. et al. [Fatal infectious mononucleosis during azathioprine treatment in Crohn’s disease]. Gastroenterol Hepatol 2000; 23: 7-8
557 N’Guyen Y, Andreoletti L, Patey M. et al. Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn’s disease. J Clin Microbiol 2009; 47: 1252-1254
558 Nissen LH, Nagtegaal ID, de Jong DJ. et al. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis 2015; 9: 398-403
559 Fries W, Cottone M, Cascio A. Systematic review: macrophage activation syndrome in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 1033-1045
560 Virdis F, Tacci S, Messina F. et al. Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn’s disease. World J Gastrointest Surg 2013; 5: 306-308
561 Klein S, Schmidt C, La Rosee P. et al. Fulminant gastrointestinal bleeding caused by EBV-triggered hemophagocytic lymphohistiocytosis: report of a case. Z Gastroenterol 2014; 52: 354-359
562 Brito-Zeron P, Bosch X, Perez-de-Lis M. et al. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheum 2016; 45: 391-399
563 Cottone M, Pietrosi G, Martorana G. et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol 2001; 96: 773-775
564 Kambham N, Vij R, Cartwright CA. et al. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28: 365-373
565 Tandon P, James P, Cordeiro E. et al. Diagnostic Accuracy of Blood-Based Tests and Histopathology for Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2017; 23: 551-560
566 Roblin X, Pillet S, Oussalah A. et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol 2011; 106: 2001-2008
567 Zidar N, Ferkolj I, Tepes K. et al. Diagnosing cytomegalovirus in patients with inflammatory bowel disease--by immunohistochemistry or polymerase chain reaction?. Virchows Arch 2015; 466: 533-539
568 Thorn M, Rorsman F, Ronnblom A. et al. Active cytomegalovirus infection diagnosed by real-time PCR in patients with inflammatory bowel disease: a prospective, controlled observational study (.). Scand J Gastroenterol 2016; 51: 1075-1080
569 Romkens TE, Bulte GJ, Nissen LH. et al. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22: 1321-1330
570 Shukla T, Singh S, Loftus Jr. EV. et al. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis. Inflamm Bowel Dis 2015; 21: 2718-2725
571 Kopylov U, Eliakim-Raz N, Szilagy A. et al. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. World J Gastroenterol 2014; 20: 2695-2703
572 Beswick L, Ye B, van Langenberg DR. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflamm Bowel Dis 2016; 22: 2966-2976
573 Kopylov U, Papamichael K, Katsanos K. et al. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis 2017; 23: 1605-1613
574 Maconi G, Colombo E, Zerbi P. et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis 2005; 37: 418-423
575 Kotton CN, Kumar D, Caliendo AM. et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360
576 Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2392-2403
577 Cote-Daigneault J, Peerani F, MacMahon E. et al. Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary. Inflamm Bowel Dis 2016; 22: 2538-2547
578 Menzies D, Adjobimey M, Ruslami R. et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 2018; 379: 440-453
579 Diallo T, Adjobimey M, Ruslami R. et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med 2018; 379: 454-463
580 Robert-Koch-Institut. Tuberkulose. RKI-Ratgeber für Ärzte. 2017 http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Tuberkulose.htm
581 Lewinsohn DM, Leonard MK, LoBue PA. et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64: 111-115
582 Julsgaard M, Christensen LA, Gibson PR. et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016; 151: 110-119
583 Lichtenstein GR, Cohen R, Yamashita B. et al. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006; 40: 669-677
584 Heuschen UA, Heuschen G, Rudek B. et al. [Long-term quality of life after continence-preserving proctocolectomy for ulcerative colitis and familial adenomatous polyposis]. Chirurg 1998; 69: 1052-1058
585 Mark-Christensen A, Erichsen R, Brandsborg S. et al. Pouch Failures Following Ileal Pouch-anal Anastomosis for Ulcerative Colitis. Colorectal Dis 2017;
586 Lovegrove RE, Tilney HS, Remzi FH. et al. To divert or not to divert: A retrospective analysis of variables that influence ileostomy omission in ileal pouch surgery. Arch Surg 2011; 146: 82-88
587 Mennigen R, Sewald W, Senninger N. et al. Morbidity of loop ileostomy closure after restorative proctocolectomy for ulcerative colitis and familial adenomatous polyposis: a systematic review. J Gastrointest Surg 2014; 18: 2192-2200
588 Lovegrove RE, Heriot AG, Constantinides V. et al. Meta-analysis of short-term and long-term outcomes of J, W and S ileal reservoirs for restorative proctocolectomy. Colorectal Dis 2007; 9: 310-320
589 McCormick PH, Guest GD, Clark AJ. et al. The ideal ileal-pouch design: a long-term randomized control trial of J- vs. W-pouch construction. Dis Colon Rectum 2012; 55: 1251-1257
590 Oresland T, Fasth S, Nordgren S. et al. A prospective randomized comparison of two different pelvic pouch designs. Scand J Gastroenterol 1990; 25: 986-996
591 Pal S, Sahni P, Pande GK. et al. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol 2005; 5: 39
592 Heppell J, Farkouh E, Dube S. et al. Toxic megacolon. An analysis of 70 cases. Dis Colon Rectum 1986; 29: 789-792
593 Fowkes L, Krishna K, Menon A. et al. Laparoscopic emergency and elective surgery for ulcerative colitis. Colorectal Dis 2008; 10: 373-378
594 Ziv Y, Fazio VW, Church JM. et al. Safety of urgent restorative proctocolectomy with ileal pouch-anal anastomosis for fulminant colitis. Dis Colon Rectum 1995; 38: 345-349
595 Heyvaert G, Penninckx F, Filez L. et al. Restorative proctocolectomy in elective and emergency cases of ulcerative colitis. Int J Colorectal Dis 1994; 9: 73-76
596 Fazio VW, Ziv Y, Church JM. et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222: 120-127
597 Sheth SG, LaMont JT. Toxic megacolon. Lancet 1998; 351: 509-513
598 Croft A, Walsh A, Doecke J. et al. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013; 38: 294-302
599 Turner D, Hyams J, Markowitz J. et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009; 15: 1218-1223
600 Turner D, Walsh CM, Benchimol EI. et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008; 57: 331-338
601 Kimura H, Kunisaki R, Tatsumi K. et al. Prolonged Medical Therapy Increases the Risk of Surgical Complications in Patients with Severe Ulcerative Colitis. Dig Surg 2016; 33: 182-189
602 Neumann PA, Mennigen RB, Senninger N. et al. Timing of restorative proctocolectomy in patients with medically refractory ulcerative colitis: the patient’s point of view. Dis Colon Rectum 2012; 55: 756-761
603 Feuerstein JD, Akbari M, Tapper EB. et al. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol 2016; 29: 341-347
604 van der Valk ME, Mangen MJ, Severs M. et al. Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFalpha Therapy. J Crohns Colitis 2015; 9: 1016-1023
605 Heuschkel R, Salvestrini C, Beattie RM. et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 839-849
606 Nicholls RJ, Holt SD, Lubowski DZ. Restorative proctocolectomy with ileal reservoir. Comparison of two-stage vs. three-stage procedures and analysis of factors that might affect outcome. Dis Colon Rectum 1989; 32: 323-326
607 Selvasekar CR, Cima RR, Larson DW. et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 956-962
608 Stewart D, Chao A, Kodner I. et al. Subtotal colectomy for toxic and fulminant colitis in the era of immunosuppressive therapy. Colorectal Dis 2009; 11: 184-190
609 Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: the price we have to pay?. Inflamm Bowel Dis 2008; 14: 1019-1021
610 Norgard BM, Nielsen J, Qvist N. et al. Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with ulcerative colitis – a nationwide cohort study. Aliment Pharmacol Ther 2012; 35: 1301-1309
611 Mor IJ, Vogel JD, da Luz Moreira A. et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51: 1202-1207
612 Yang Z, Wu Q, Wang F. et al. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36: 922-928
613 Selvaggi F, Pellino G, Canonico S. et al. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis 2015; 21: 79-92
614 Kulaylat AS, Kulaylat AN, Schaefer EW. et al. Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis. JAMA Surg 2017; 152: e171538
615 Lau C, Dubinsky M, Melmed G. et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015; 261: 487-496
616 Hait EJ, Bousvaros A, Schuman M. et al. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J Pediatr Surg 2007; 42: 31-34
617 Gu J, Stocchi L, Remzi F. et al. Intraperitoneal or subcutaneous: does location of the (colo)rectal stump influence outcomes after laparoscopic total abdominal colectomy for ulcerative colitis?. Dis Colon Rectum 2013; 56: 615-621
618 Trickett JP, Tilney HS, Gudgeon AM. et al. Management of the rectal stump after emergency sub-total colectomy: which surgical option is associated with the lowest morbidity?. Colorectal Dis 2005; 7: 519-522
619 Karch LA, Bauer JJ, Gorfine SR. et al. Subtotal colectomy with Hartmann’s pouch for inflammatory bowel disease. Dis Colon Rectum 1995; 38: 635-639
620 Bartels SA, Gardenbroek TJ, Aarts M. et al. Short-term morbidity and quality of life from a randomized clinical trial of close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis. Br J Surg 2015; 102: 281-287
621 Hicks CW, Hodin RA, Savitt L. et al. Does intramesorectal excision for ulcerative colitis impact bowel and sexual function when compared with total mesorectal excision?. Am J Surg 2014; 208: 499-504 e4
622 Rink AD, Radinski I, Vestweber KH. Does mesorectal preservation protect the ileoanal anastomosis after restorative proctocolectomy?. J Gastrointest Surg 2009; 13: 120-128
623 Lovegrove RE, Constantinides VA, Heriot AG. et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. Ann Surg 2006; 244: 18-26
624 Schluender SJ, Mei L, Yang H. et al. Can a meta-analysis answer the question: is mucosectomy and handsewn or double-stapled anastomosis better in ileal pouch-anal anastomosis?. Am Surg 2006; 72: 912-916
625 Ganschow P, Treiber I, Hinz U. et al. Residual rectal mucosa after stapled vs. handsewn ileal J-pouch-anal anastomosis in patients with familial adenomatous polyposis coli (FAP)--a critical issue. Langenbecks Arch Surg 2015; 400: 213-219
626 Ota H, Yamazaki K, Endoh W. et al. Adenocarcinoma arising below an ileoanal anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case. Surg Today 2007; 37: 596-599
627 Alessandroni L, Kohn A, Capaldi M. et al. Adenocarcinoma below stapled ileoanal anastomosis after restorative proctocolectomy for ulcerative colitis. Updates Surg 2012; 64: 149-152
628 Al-Sukhni W, McLeod RS, MacRae H. et al. Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. Dis Colon Rectum 2010; 53: 1495-1500
629 Oresland T, Bemelman WA, Sampietro GM. et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis 2015; 9: 4-25
630 Tekkis PP, Fazio VW, Lavery IC. et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg 2005; 241: 262-268
631 Parc Y, Reboul-Marty J, Lefevre JH. et al. Restorative Proctocolectomy and Ileal Pouch-anal Anastomosis. Ann Surg 2015; 262: 849-853
632 Burns EM, Bottle A, Aylin P. et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011; 98: 408-417
633 Raval MJ, Schnitzler M, O’Connor BI. et al. Improved outcome due to increased experience and individualized management of leaks after ileal pouch-anal anastomosis. Ann Surg 2007; 246: 763-770
634 Borjesson L, Willen R, Haboubi N. et al. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term term follow-up study. Colorectal Dis 2004; 6: 494-498
635 Pachler FR, Brandsborg SB, Laurberg S. Paradoxical Impact of Ileal Pouch-Anal Anastomosis on Male and Female Fertility in Patients With Ulcerative Colitis. Dis Colon Rectum 2017; 60: 603-607
636 Uzzan M, Cosnes J, Amiot A. et al. Long-term Follow-up After Ileorectal Anastomosis for Ulcerative Colitis: A GETAID/GETAID Chirurgie Multicenter Retrospective Cohort of 343 Patients. Ann Surg 2017; 266: 1029-1034
637 Borjesson L, Lundstam U, Oresland T. et al. The place for colectomy and ileorectal anastomosis: a valid surgical option for ulcerative colitis?. Tech Coloproctol 2006; 10: 237-241
638 da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg 2010; 97: 65-69
639 Soravia C, O’Connor BI, Berk T. et al. Functional outcome of conversion of ileorectal anastomosis to ileal pouch-anal anastomosis in patients with familial adenomatous polyposis and ulcerative colitis. Dis Colon Rectum 1999; 42: 903-908
640 Nessar G, Fazio VW, Tekkis P. et al. Long-term outcome and quality of life after continent ileostomy. Dis Colon Rectum 2006; 49: 336-344
641 Berndtsson I, Lindholm E, Ekman I. Thirty years of experience living with a continent ileostomy: bad restrooms--not my reservoir--decide my life. J Wound Ostomy Continence Nurs 2005; 32: 321-326
642 Litle VR, Barbour S, Schrock TR. et al. The continent ileostomy: long-term durability and patient satisfaction. J Gastrointest Surg 1999; 3: 625-632
643 Lian L, Fazio VW, Remzi FH. et al. Outcomes for patients undergoing continent ileostomy after a failed ileal pouch-anal anastomosis. Dis Colon Rectum 2009; 52: 1409-1414
644 Uzzan M, Kirchgesner J, Oubaya N. et al. Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. J Crohns Colitis 2017; 11: 930-935
645 Kuiper T, Vlug MS, van den Broek FJ. et al. The prevalence of dysplasia in the ileoanal pouch following restorative proctocolectomy for ulcerative colitis with associated dysplasia. Colorectal Dis 2012; 14: 469-473
646 Maartense S, Dunker MS, Slors JF. et al. Hand-assisted laparoscopic versus open restorative proctocolectomy with ileal pouch anal anastomosis: a randomized trial. Ann Surg 2004; 240: 984-991
647 Tilney HS, Lovegrove RE, Heriot AG. et al. Comparison of short-term outcomes of laparoscopic vs. open approaches to ileal pouch surgery. Int J Colorectal Dis 2007; 22: 531-542
648 Ahmed Ali U, Keus F, Heikens JT. et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev 2009; CD006267
649 Bartels SA, Gardenbroek TJ, Ubbink DT. et al. Systematic review and meta-analysis of laparoscopic versus open colectomy with end ileostomy for non-toxic colitis. Br J Surg 2013; 100: 726-733
650 Wu XJ, He XS, Zhou XY. et al. The role of laparoscopic surgery for ulcerative colitis: systematic review with meta-analysis. Int J Colorectal Dis 2010; 25: 949-957
651 Beyer-Berjot L, Maggiori L, Birnbaum D. et al. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg 2013; 258: 275-282
652 Bartels SA, Vlug MS, Henneman D. et al. Less adhesiolysis and hernia repair during completion proctocolectomy after laparoscopic emergency colectomy for ulcerative colitis. Surg Endosc 2012; 26: 368-373
653 Indar AA, Efron JE, Young-Fadok TM. Laparoscopic ileal pouch-anal anastomosis reduces abdominal and pelvic adhesions. Surg Endosc 2009; 23: 174-177
654 Bartels SA, D’Hoore A, Cuesta MA. et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 2012; 256: 1045-1048
655 Benlice C, Stocchi L, Costedio M. et al. Laparoscopic IPAA is not associated with decreased rates of incisional hernia and small-bowel obstruction when compared with open technique: long-term follow-up of a case-matched study. Dis Colon Rectum 2015; 58: 314-320
656 Holubar SD, Larson DW, Dozois EJ. et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach?. Dis Colon Rectum 2009; 52: 187-192
657 Chung TP, Fleshman JW, Birnbaum EH. et al. Laparoscopic vs. open total abdominal colectomy for severe colitis: impact on recovery and subsequent completion restorative proctectomy. Dis Colon Rectum 2009; 52: 4-10
658 Telem DA, Vine AJ, Swain G. et al. Laparoscopic subtotal colectomy for medically refractory ulcerative colitis: the time has come. Surg Endosc 2010; 24: 1616-1620
659 Geboes K, Colombel JF, Greenstein A. et al. Indeterminate colitis: a review of the concept – what’s in a name?. Inflamm Bowel Dis 2008; 14: 850-857
660 Pishori T, Dinnewitzer A, Zmora O. et al. Outcome of patients with indeterminate colitis undergoing a double-stapled ileal pouch-anal anastomosis. Dis Colon Rectum 2004; 47: 717-721
661 Delaney CP, Remzi FH, Gramlich T. et al. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg 2002; 236: 43-48
662 Reese GE, Lovegrove RE, Tilney HS. et al. The effect of Crohn’s disease on outcomes after restorative proctocolectomy. Dis Colon Rectum 2007; 50: 239-250
663 Malaty HM, Fan X, Opekun AR. et al. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr 2010; 50: 27-31
664 Svaninger G, Nordgren S, Oresland T. et al. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol 1993; 28: 695-700
665 Rauh SM, Schoetz Jr. DJ, Roberts PL. et al. Pouchitis--is it a wastebasket diagnosis?. Dis Colon Rectum 1991; 34: 685-689
666 Sandborn WJ, Tremaine WJ, Batts KP. et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994; 69: 409-415
667 Tiainen J, Matikainen M. Long-term clinical outcome and anemia after restorative proctocolectomy for ulcerative colitis. Scand J Gastroenterol 2000; 35: 1170-1173
668 Meagher AP, Farouk R, Dozois RR. et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998; 85: 800-803
669 Hurst RD, Chung TP, Rubin M. et al. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis 1998; 4: 280-284
670 Tiainen J, Matikainen M, Aitola P. et al. Histological and macroscopic changes in the pelvic pouch: long-term follow up after restorative proctocolectomy for ulcerative colitis (UC). Colorectal Dis 2001; 3: 28-32
671 Tiainen J, Matikainen M. Health-related quality of life after ileal J-pouch-anal anastomosis for ulcerative colitis: long-term results. Scand J Gastroenterol 1999; 34: 601-605
672 Seidel SA, Peach SE, Newman M. et al. Ileoanal pouch procedures: clinical outcomes and quality-of-life assessment. Am Surg 1999; 65: 40-46
673 Heuschen UA, Autschbach F, Allemeyer EH. et al. Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 2001; 44: 487-499
674 Stahlberg D, Gullberg K, Liljeqvist L. et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996; 39: 1012-1018
675 Lohmuller JL, Pemberton JH, Dozois RR. et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990; 211: 622-627
676 Nicholls RJ, Banerjee AK. Pouchitis: risk factors, etiology, and treatment. World J Surg 1998; 22: 347-351
677 Penna C, Dozois R, Tremaine W. et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-239
678 Shen B, Achkar JP, Lashner BA. et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002; 97: 972-977
679 Thoeni RF, Fell SC, Engelstad B. et al. Ileoanal pouches: comparison of CT, scintigraphy, and contrast enemas for diagnosing postsurgical complications. Am J Roentgenol 1990; 154: 73-78
680 Libicher M, Scharf J, Wunsch A. et al. MRI of pouch-related fistulas in ulcerative colitis after restorative proctocolectomy. J Comput Assist Tomogr 1998; 22: 664-668
681 Hrung JM, Levine MS, Rombeau JL. et al. Total proctocolectomy and ileoanal pouch: the role of contrast studies for evaluating postoperative leaks. Abdom Imaging 1998; 23: 375-379
682 Solomon MJ, McLeod RS, O’Connor BI. et al. Assessment of peripouch inflammation after ileoanal anastomosis using endoluminal ultrasonography. Dis Colon Rectum 1995; 38: 182-187
683 Segal JP, Ding NS, Worley G. et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther 2017; 45: 581-592
684 Sandborn W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev 2000; CD001176
685 Sandborn WJ, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis 1999; 5: 33-39
686 Singh S, Stroud AM, Holubar SD. et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2015; CD001176
687 Mimura T, Rizzello F, Helwig U. et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16: 909-917
688 Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-1196
689 Shen B, Achkar JP, Lashner BA. et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-305
690 Hurst RD, Molinari M, Chung TP. et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131: 497-500
691 Shen B, Fazio VW, Remzi FH. et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007; 50: 498-508
692 Gionchetti P, Rizzello F, Venturi A. et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13: 713-718
693 Nygaard K, Bergan T, Bjorneklett A. et al. Topical metronidazole treatment in pouchitis. Scand J Gastroenterol 1994; 29: 462-467
694 Abdelrazeq AS, Kelly SM, Lund JN. et al. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005; 7: 182-186
695 Gionchetti P, Rizzello F, Poggioli G. et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25: 1231-1236
696 Sambuelli A, Boerr L, Negreira S. et al. Budesonide enema in pouchitis – a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16: 27-34
697 Travis S, Silverberg M, Danese S. et al. Efficacy and safety of intravenous vedolizumab for treatment of chronic pouchitis: results of the phase 4 earnest trial. United european gastroenterology journal 2021; 9 (Suppl. 08) 531-532
698 Herfarth HH, Long MD, Isaacs KL. Use of Biologics in Pouchitis: A Systematic Review. J Clin Gastroenterol 2015; 49: 647-654
699 Kelly OB, Rosenberg M, Tyler AD. et al. Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis. J Crohns Colitis 2016; 10: 410-417
700 Li Y, Lopez R, Queener E. et al. Adalimumab therapy in Crohn’s disease of the ileal pouch. Inflamm Bowel Dis 2012; 18: 2232-2239
701 Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J. et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012; 24: 756-758
702 Mir F, Yousef MH, Partyka EK. et al. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis 2017; 32: 1517-1518
703 Tran-Minh ML, Allez M, Gornet JM. Successful Treatment With Ustekinumab for Chronic Refractory Pouchitis. J Crohns Colitis 2017; 11: 1156
704 Winter TA, Dalton HR, Merrett MN. et al. Cyclosporin A retention enemas in refractory distal ulcerative colitis and “pouchitis”. Scand J Gastroenterol 1993; 28: 701-704
705 Fang S, Kraft CS, Dhere T. et al. Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report. Int J Colorectal Dis 2016; 31: 1093-1094
706 Schmid M, Frick JS, Malek N. et al. Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis. Int J Colorectal Dis 2017; 32: 597-598
707 Miner P, Wedel M, Bane B. et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19: 281-286
708 Shen B, Remzi FH, Lopez AR. et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008; 8: 26
709 Greuter T, Biedermann L, Rogler G. et al. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterol J 2016; 4: 97-104
710 Shen B, Remzi FH, Lavery IC. et al. Administration of adalimumab in the treatment of Crohn’s disease of the ileal pouch. Aliment Pharmacol Ther 2009; 29: 519-526
711 Holubar SD, Cima RR, Sandborn WJ. et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010; CD001176
712 Mimura T, Rizzello F, Helwig U. et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114
713 Gionchetti P, Rizzello F, Venturi A. et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309
714 Zhu H, Wu XR, Queener E. et al. Clinical value of surveillance pouchoscopy in asymptomatic ileal pouch patients with underlying inflammatory bowel disease. Surg Endosc 2013; 27: 4325-4332
715 Gullberg K, Lindforss U, Zetterquist H. et al. Cancer risk assessment in long-standing pouchitis. DNA aberrations are rare in transformed neoplastic pelvic pouch mucosa. Int J Colorectal Dis 2002; 17: 92-97
716 Hashimoto T, Itabashi M, Ogawa S. et al. Treatment strategy for preventing pouchitis as a postoperative complication of ulcerative colitis: the significance of the management of cuffitis. Surg Today 2014; 44: 1730-1734
717 Shen B, Lashner BA, Bennett AE. et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004; 99: 1527-1531
718 Shen B, Sanmiguel C, Bennett AE. et al. Irritable pouch syndrome is characterized by visceral hypersensitivity. Inflamm Bowel Dis 2011; 17: 994-1002
719 Jantchou P, Morois S, Clavel-Chapelon F. et al. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol 2010; 105: 2195-2201
720 Ananthakrishnan AN, Khalili H, Konijeti GG. et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut 2014; 63: 776-784
721 Ananthakrishnan AN, Khalili H, Konijeti GG. et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology 2013; 145: 970-977
722 Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 39: 125-136
723 Klement E, Reif S. Breastfeeding and risk of inflammatory bowel disease. Am J Clin Nutr 2005; 82: 486
724 Barclay AR, Russell RK, Wilson ML. et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 2009; 155: 421-426
725 Gearry RB, Richardson AK, Frampton CM. et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010; 25: 325-333
726 Hansen TS, Jess T, Vind I. et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis 2011; 5: 577-584
727 Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008; 52: 867-874
728 Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008; 14: 1105-1111
729 Massironi S, Rossi RE, Cavalcoli FA. et al. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr 2013; 32: 904-910
730 Han YM, Yoon H, Lim S. et al. Risk Factors for Vitamin D, Zinc, and Selenium Deficiencies in Korean Patients with Inflammatory Bowel Disease. Gut Liver 2017;
731 Oikonomou IK, Fazio VW, Remzi FH. et al. Risk factors for anemia in patients with ileal pouch-anal anastomosis. Dis Colon Rectum 2007; 50: 69-74
732 Pastrana RJ, Torres EA, Arroyo JM. et al. Iron-deficiency anemia as presentation of pouchitis. J Clin Gastroenterol 2007; 41: 41-44
733 Kuisma J, Nuutinen H, Luukkonen P. et al. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001; 96: 3110-3116
734 M’Koma AE. Follow-up results of hematology data before and after restorative proctocolectomy. Clinical outcome. Dis Colon Rectum 1994; 37: 932-937
735 Bischoff SC, Koletzko B, Lochs H. et al. Klinische Ernährung in der Gastroenterologie (Teil 4) – Chronisch-entzündliche Darmerkrankungen. Aktuel Ernahrungsmed 2014; 39: e72-e98
736 Turner D, Zlotkin SH, Shah PS. et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; CD006320
737 Turner D, Shah PS, Steinhart AH. et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 2011; 17: 336-345
738 Steinhart AH, Hiruki T, Brzezinski A. et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996; 10: 729-736
739 Akobeng AK, Elawad M, Gordon M. Glutamine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2016; 2: CD007348
740 Roediger WE, Duncan A, Kapaniris O. et al. Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 1993; 104: 802-809
741 Lochs H, Dejong C, Hammarqvist F. et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 2006; 25: 260-274
742 Schulz RJ, Bischoff SC, Koletzko B. et al. Gastroenterology – Guidelines on Parenteral Nutrition, Chapter 15. Ger Med Sci 2009; 7: Doc13
743 Forbes A, Escher J, Hebuterne X. et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017; 36: 321-347
744 Song HK, Buzby GP. Nutritional support for Crohn’s disease. Surg Clin North Am 2001; 81: 103-115, viii
745 Nguyen DL, Parekh NK, Jamal MM. National Trends and Outcomes of Inflammatory Bowel Disease Patients Requiring in-Hospital Total Parenteral Nutrition Support. Gastroenterology 2013; 144: S749-S749
746 Bischoff SC, Fleig W. [Ulcerative colitis. Nutrition]. Z Gastroenterol 2004; 42: 998-1002
747 Stein J. Leitlinien Morbus Crohn. Z Gastroenterol 2003; 41: 62-68
748 Dignass AU, Gasche C, Bettenworth D. et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211-222
749 Martin J, Radeke HH, Dignass A. et al. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2017; 11: 19-32
750 Evstatiev R, Marteau P, Iqbal T. et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-853 e1-2
751 Wolman SL, Anderson GH, Marliss EB. et al. Zinc in total parenteral nutrition: requirements and metabolic effects. Gastroenterology 1979; 76: 458-467
752 Jeejeebhoy K. Zinc: an essential trace element for parenteral nutrition. Gastroenterology 2009; 137: S7-S12
753 Schölmerich J, Freudemann A, Köttgen E. et al. Bioavailability of zinc from zinc-histidine complexes. I. Comparison with zinc sulfate in healthy men. Am J Clin Nutr 1987; 45: 1480-1486
754 Rossi RE, Whyand T, Murray CD. et al. The role of dietary supplements in inflammatory bowel disease: a systematic review. Eur J Gastroenterol Hepatol 2016; 28: 1357-1364
755 Fessler TA. Trace elements in parenteral nutrition: a practical guide for dosage and monitoring for adult patients. Nutr Clin Pract 2013; 28: 722-729
756 Kruis W, Phuong Nguyen G. Iron Deficiency, Zinc, Magnesium, Vitamin Deficiencies in Crohn’s Disease: Substitute or Not?. Dig Dis 2016; 34: 105-111
757 Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much?. J Crohns Colitis 2015; 9: 198-209
758 Raftery T, O’Sullivan M. Optimal vitamin D levels in Crohn’s disease: a review. Proc Nutr Soc 2015; 74: 56-66
759 Lee JA, Hwang JS, Hwang IT. et al. Low vitamin D levels are associated with both iron deficiency and anemia in children and adolescents. Pediatr Hematol Oncol 2015; 32: 99-108
760 Schlereth F, Badenhoop K. [Vitamin D: More than just a bone hormone]. Internist (Berl) 2016; 57: 646-655
761 Ng SC, Plamondon S, Kamm MA. et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1286-1298
762 Pramyothin P, Holick MF. Vitamin D supplementation: guidelines and evidence for subclinical deficiency. Curr Opin Gastroenterol 2012; 28: 139-150
763 Higgens CS, Keighley MR, Allan RN. Impact of preoperative weight loss and body composition changes on postoperative outcome in surgery for inflammatory bowel disease. Gut 1984; 25: 732-736
764 Lindor KD, Fleming CR, Ilstrup DM. Preoperative nutritional status and other factors that influence surgical outcome in patients with Crohn’s disease. Mayo Clin Proc 1985; 60: 393-396
765 Rombeau JL, Barot LR, Williamson CE. et al. Preoperative total parenteral nutrition and surgical outcome in patients with inflammatory bowel disease. Am J Surg 1982; 143: 139-143
766 Schwartz E. Perioperative Parenteral Nutrition in Adults With Inflammatory Bowel Disease: A Review of the Literature. Nutr Clin Pract 2016; 31: 159-170
767 Weimann A, Braga M, Harsanyi L. et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr 2006; 25: 224-244
768 Sorensen J, Kondrup J, Prokopowicz J. et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr 2008; 27: 340-349
769 Weimann A, Breitenstein S, Breuer JP. et al. [Clinical nutrition in surgery. Guidelines of the German Society for Nutritional Medicine]. Chirurg 2014; 85: 320-326
770 Stein J. Kurzdarmsyndrom – Chronisches Darmversagen. In: E.D. S, ed. Entzündliche Darmerkrankungen. Stuttgart: Schattauer; 2015: 361-386
771 M’Koma AE, Wise PE, Schwartz DA. et al. Prevalence and outcome of anemia after restorative proctocolectomy: a clinical literature review. Dis Colon Rectum 2009; 52: 726-739
772 Stein J, Connor S, Virgin G. et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol 2016; 22: 7908-7925
773 M’Koma AE. Serum biochemical evaluation of patients with functional pouches ten to 20 years after restorative proctocolectomy. Int J Colorectal Dis 2006; 21: 711-720
774 Khanna R, Wu X, Shen B. Low levels of vitamin D are common in patients with ileal pouches irrespective of pouch inflammation. J Crohns Colitis 2013; 7: 525-533
775 Wieland LS, Manheimer E, Berman BM. Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med 2011; 17: 50-59
776 Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; 10 (12) 1-23
777 Bensoussan M, Jovenin N, Garcia B. et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol 2006; 30: 14-23
778 Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use?. Am J Gastroenterol 2004; 99: 889-893
779 Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: An Internet survey. Can J Gastroenterol 1999; 13: 327-332
780 Hilsden RJ, Verhoef MJ, Rasmussen H. et al. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 655-662
781 Kong SC, Hurlstone DP, Pocock CY. et al. The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005; 39: 138-141
782 Langhorst J, Anthonisen IB, Steder-Neukamm U. et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005; 11: 287-295
783 Langhorst J, Wulfert H, Lauche R. et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 86-106
784 Elsenbruch S, Langhorst J, Popkirowa K. et al. Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom 2005; 74: 277-287
785 Langhorst J, Mueller T, Luedtke R. et al. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand J Gastroenterol 2007; 42: 734-745
786 Berrill JW, Sadlier M, Hood K. et al. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis 2014; 8: 945-955
787 Jedel S, Hoffman A, Merriman P. et al. A randomized controlled trial of mindfulness-based stress reduction to prevent flare-up in patients with inactive ulcerative colitis. Digestion 2014; 89: 142-155
788 Mizrahi MC, Reicher-Atir R, Levy S. et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychology and Health 2012; 27: 1463-1479
789 Shaw L, Ehrlich A. Relaxation training as a treatment for chronic pain caused by ulcerative colitis. Pain 1987; 29: 287-293
790 Gerbarg PL, Jacob VE, Stevens L. et al. The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial. Inflammatory Bowel Diseases 2015; 21: 2886-2896
791 Klare P, Nigg J, Nold J. et al. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: A prospective randomized controlled trial. Digestion 2015; 91: 239-247
792 Packer N, Hoffman-Goetz L, Ward G. Does physical activity affect quality of life, disease symptoms and immune measures in patients with inflammatory bowel disease? A systematic review. Journal of Sports Medicine and Physical Fitness 2010; 50: 1-18
793 Sharma P, Poojary G, Velez DM. et al. Effect of Yoga-Based Intervention in Patients with Inflammatory Bowel Disease. Int J Yoga Therap 2015; 25: 101-112
794 Cramer H, Schafer M, Schols M. et al. Randomised clinical trial: yoga vs. written self-care advice for ulcerative colitis. Aliment Pharmacol Ther 2017;
795 Schneider A, Streitberger K, Joos S. Acupuncture treatment in gastrointestinal diseases: A systematic review. World J Gastroenterol 2007; 13: 3417-3424
796 Joos S, Wildau N, Kohnen R. et al. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 2006; 41: 1056-1063
797 Ji J, Lu Y, Liu H. et al. Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2013; 2013: 158352
798 Lee DH, Kim JI, Lee MS. et al. Moxibustion for ulcerative colitis: a systematic review and meta-analysis. BMC Gastroenterol 2010; 10: 36
799 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL. et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433
800 Hanai H, Iida T, Takeuchi K. et al. Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology 2006; 4: 1502-1506
801 Singla V, Pratap Mouli V, Garg SK. et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014; 8: 208-214
802 Lang A, Salomon N, Wu JCY. et al. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 2015; 13: 1444-1449.e1
803 Langhorst J, Varnhagen I, Schneider SB. et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 2013; 38: 490-500
804 Albrecht U, Muller V, Schneider B. et al. Efficacy and safety of a herbal medicinal product containing myrrh, chamomile and coffee charcoal for the treatment of gastrointestinal disorders: a non-interventional study. BMJ Open Gastroenterol 2014; 1: e000015
805 Langhorst J, Lauche R, Koch AK. Myrrhe, Kamille und Kaffeekohle in der Therapie von Patienten mit Colitis ulcerosa. Eine retrospektive Kohortenstudie mit 5-Jahres-Follow-up. Zeitschrift für Phytotherapie 2016; 37: 249-253
806 Kamali M, Tavakoli H, Khodadoost M. et al. Efficacy of the Punica granatum peels aqueous extract for symptom management in ulcerative colitis patients. A randomized, placebo-controlled, clinical trial. Complement Ther Clin Pract 2015; 21: 141-146
807 Gupta I, Parihar A, Malhotra P. et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001; 67: 391-395
808 Gupta I, Parihar A, Malhotra P. et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997; 2: 37-43
809 Tang T, Targan SR, Li ZS. et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2011; 33: 194-202
810 Sandborn WJ, Targan SR, Byers VS. et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013; 108: 90-98
811 Ben-Arye E, Goldin E, Wengrower D. et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002; 37: 444-449
812 Greenfield SM, Green AT, Teare JP. et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 1993; 7: 159-166
813 Langmead L, Feakins RM, Goldthorpe S. et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 739-747
814 Rastegarpanah M, Malekzadeh R, Vahedi H. et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. Chin J Integr Med 2015; 21: 902-906
815 Tong ZQ, Yang B, Chen BY. et al. A multi-center, randomized, single-blind, controlled clinical study on the efficacy of composite sophora colon-soluble capsules in treating ulcerative colitis. Chin J Integr Med 2010; 16: 486-492
816 Biedermann L, Mwinyi J, Scharl M. et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – an open pilot study. J Crohns Colitis 2013; 7: 271-279
817 Pullan RD, Rhodes J, Ganesh S. et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811-815
818 Sandborn WJ, Tremaine WJ, Offord KP. et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 364-371
819 Thomas GA, Rhodes J, Mani V. et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332: 988-992
820 Thomas GA, Rhodes J, Ragunath K. et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 769-776
821 Pagoldh M, Hultgren E, Arnell P. et al. Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: A prospective randomized study. Scand J Gastroenterol 2013; 48: 1033-1040
822 Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev 2014; CD009400
823 Summers RW, Elliott DE, Urban Jr. JF. et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005; 128: 825-832
824 Scholmerich J, Fellermann K, Seibold FW. et al. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn’s Disease. J Crohns Colitis 2017; 11: 390-399

Zusatzmaterial

Zusatzmaterial